A trial to study the cardiovascular toxicity of abiraterone acetate in metastatic Castration Resistant Prostate Cancer (mCRPC) patients with cardiovascular comorbidities or CAD (coronary artery disease) risk factors

Trial Profile

A trial to study the cardiovascular toxicity of abiraterone acetate in metastatic Castration Resistant Prostate Cancer (mCRPC) patients with cardiovascular comorbidities or CAD (coronary artery disease) risk factors

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Aug 2016

At a glance

  • Drugs Abiraterone acetate (Primary) ; Prednisone
  • Indications Prostate cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 08 Aug 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top